User login
Key clinical point: The presence of synchronous ovarian metastases was not associated with a reduced 3-year overall survival (OS) in females with stage IV colorectal cancer (CRC).
Major finding: The 3-year OS rate was not significantly different between patients with vs without ovarian metastases (6.8% vs 8.0%; P = .607), with the median OS not being significantly different among patients with vs without ovarian metastases (adjusted hazard ratio 0.81; 95% CI 0.61-1.09).
Study details: The data come from a propensity score-matched analysis including 5253 female patients with stage IV CRC who received systemic therapy with palliative intent, of which 159 women with ovarian metastases were propensity matched with 159 women without ovarian metastases.
Disclosures: No information on funding source was available. No conflicts of interest were declared.
Source: van der Meer R et al. A propensity score-matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases. Int J Cancer. 2022 (Oct 17). Doi: 10.1002/ijc.343205
Key clinical point: The presence of synchronous ovarian metastases was not associated with a reduced 3-year overall survival (OS) in females with stage IV colorectal cancer (CRC).
Major finding: The 3-year OS rate was not significantly different between patients with vs without ovarian metastases (6.8% vs 8.0%; P = .607), with the median OS not being significantly different among patients with vs without ovarian metastases (adjusted hazard ratio 0.81; 95% CI 0.61-1.09).
Study details: The data come from a propensity score-matched analysis including 5253 female patients with stage IV CRC who received systemic therapy with palliative intent, of which 159 women with ovarian metastases were propensity matched with 159 women without ovarian metastases.
Disclosures: No information on funding source was available. No conflicts of interest were declared.
Source: van der Meer R et al. A propensity score-matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases. Int J Cancer. 2022 (Oct 17). Doi: 10.1002/ijc.343205
Key clinical point: The presence of synchronous ovarian metastases was not associated with a reduced 3-year overall survival (OS) in females with stage IV colorectal cancer (CRC).
Major finding: The 3-year OS rate was not significantly different between patients with vs without ovarian metastases (6.8% vs 8.0%; P = .607), with the median OS not being significantly different among patients with vs without ovarian metastases (adjusted hazard ratio 0.81; 95% CI 0.61-1.09).
Study details: The data come from a propensity score-matched analysis including 5253 female patients with stage IV CRC who received systemic therapy with palliative intent, of which 159 women with ovarian metastases were propensity matched with 159 women without ovarian metastases.
Disclosures: No information on funding source was available. No conflicts of interest were declared.
Source: van der Meer R et al. A propensity score-matched analysis of oncological outcome after systemic therapy for stage IV colorectal cancer: Impact of synchronous ovarian metastases. Int J Cancer. 2022 (Oct 17). Doi: 10.1002/ijc.343205